溶血性贫血治疗进展

自身免疫性溶血性贫血(AIHA)作为血液科和普内科的常见疾病,其本质为患者体内产生结合在红细胞表面的自身抗体,导致以红细胞破坏为核心环节的贫血.AIHA的诊断需要结合自身抗体的类型和溶血相关特点.AIHA的治疗以皮质激素、免疫抑制剂和脾脏切除术为主.近年来,由于抗CD20单抗等新药出现,AIHA的治疗有了更多的选择,尤其是对于常规一线治疗失败的患者.

Advances in the treatment of hemolytic anemia

Autoimmune hemolytic anemia （AIHA） is one of the challenges for hematologists or general physicians.It is characterized by autoantibody production,which can bind on red blood cell（RBC） membrane and lead to RBCs destruction.Diagnosis of AIHA should be made according to the types of its autoantibody and the features of haemolysis.To date,the major therapy strategies include steroids,immunosuppressants and splenectomy.Newly developed treatments such as anti-CD20 monoclonal antibody are also good alternatives for patients with refractory and relapsed AIHA.